United Kingdom & American Society of Clinical Oncology

United Kingdom: The United Kingdom is a key participant in the OPTIMA trial, with its National Health Service (NHS) poised to benefit from the adoption of the Prosigna test, potentially sparing thousands of patients from unnecessary chemotherapy and reducing healthcare costs.

American Society of Clinical Oncology: The American Society of Clinical Oncology is hosting its annual meeting where the groundbreaking results of the OPTIMA trial are being presented, disseminating the findings to a global audience of cancer specialists.

United Kingdom: The United Kingdom>>> is one of the 11 countries where the OrigAMI-4 trial was conducted, and its healthcare system, particularly Royal Marsden Hospital, played a role in patient recruitment and treatment.

American Society of Clinical Oncology: The results of the amivantamab trial are being presented at the annual meeting of the American Society of Clinical Oncology, providing a platform for wider recognition of the breakthrough.

United Kingdom: The United Kingdom is urged to make clinical trials for Daraxonrasib available and fast-track its approval to benefit Pancreatic cancer patients.

American Society of Clinical Oncology: The American Society of Clinical Oncology meeting in Chicago was the venue where the significant findings of the daraxonrasib study were presented to the medical community.

American Society of Clinical Oncology: The American Society of Clinical Oncology featured the study findings at its annual meeting, with its chief medical officer, Julie Gralow, endorsing the high quality of evidence presented.